Table 1 Incidence of Treatment-Related Toxicity by Treatment Arm

From: Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Toxicity Category

VRd (n=23)

Vd (n=25)

 

Grade

Grade

N (%)

1,2

3

4

1,2

3

4

Blood

3 (13%)

-

4 (17%)

7 (28%)

1 (4%)

3 (12%)

Constitutional

5 (22%)

3 (4%)

-

5 (20%)

5 (20%)

-

Gastrointestinal

3 (13%)

2 (9%)

-

4 (16%)

4 (16%)

-

Infection

-

1 (4%)

-

-

4 (16%)

-

Metabolic

2 (9%)

2 (9%)

-

2 (8%)

-

-

Neurologic

4 (17%)

8 (35%)

-

3 (12%)

6 (24%)

1 (4%)

Pain

2 (9%)

3 (13%)

-

2 (8%)

3 (12%)

1 (4%)

WORST DEGREE (Non-Hematologic)

2 (9%)

15 (65%)

-

4 (16%)

15 (60%)

1 (4%)